Customizable, downloadable patient education material in English and Spanish for healthcare professionals and patients. Resources covering every stage of patient care.
http://www.astellasresources.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Thursday
LOAD TIME
0.9 seconds
16x16
32x32
64x64
PAGES IN
THIS WEBSITE
0
SSL
EXTERNAL LINKS
35
SITE IP
191.238.8.26
LOAD TIME
0.914 sec
SCORE
6.2
Astellas Resource Portal | Patient Care Support | astellasresources.com Reviews
https://astellasresources.com
Customizable, downloadable patient education material in English and Spanish for healthcare professionals and patients. Resources covering every stage of patient care.
Drug-to-drug Interactions | MYRBETRIQ® (mirabegron)
https://www.myrbetriqhcp.com/drug-interactions
Myrbetriq is contraindicated in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet. Myrbetriq can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Myrbetriq is not recommended for use in severe uncontrolled hypertensive patients (defined as systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg. Please see additional Important Safety Information below. Mirabegron) is a...
Customer Support | MYRBETRIQ® (mirabegron)
https://www.myrbetriqhcp.com/customer-reimbursement
Myrbetriq is contraindicated in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet. Myrbetriq can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Myrbetriq is not recommended for use in severe uncontrolled hypertensive patients (defined as systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg. Please see additional Important Safety Information below. Can determine wh...
Momentum Program | MYRBETRIQ® (mirabegron)
https://www.myrbetriqhcp.com/momentum-savings-program
Myrbetriq is contraindicated in patients who have known hypersensitivity reactions to mirabegron or any component of the tablet. Myrbetriq can increase blood pressure. Periodic blood pressure determinations are recommended, especially in hypertensive patients. Myrbetriq is not recommended for use in severe uncontrolled hypertensive patients (defined as systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥ 110 mm Hg. Please see additional Important Safety Information below. Access to tools ...
Astellas Access Program (AAP) | Astellas Access Services (AAS)
https://www.vesicarehcp.com/astellas-access-program-services
VESIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product. Please see additional Important Safety Information below. Access Program and Services. VESIcare has the most lives with preferred brand formulary status. Preferred and total brand coverage of Commercial plans. FORMULARY STATUS DOES NOT IMPLY SAFETY OR EFFICACY OF ANY PRODUCT. When your patients join the Momentum. Patient is responsibl...
Market Experience | VESIcare® (solifenacin succinate) Tablets
https://www.vesicarehcp.com/experience
VESIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product. Please see additional Important Safety Information below. VESIcare has the most lives with. Preferred brand formulary status. FORMULARY STATUS DOES NOT IMPLY SAFETY OR EFFICACY OF ANY PRODUCT. A product’s placement on a plan’s formulary involves a variety of factors known only to the applicable plan. NEXT: Mechanism of Action. The neu...
Urine Volume Voided | VESIcare® (solifenacin succinate) Tablets
https://www.vesicarehcp.com/urine-volume-voided
VESIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product. Please see additional Important Safety Information below. VESIcare has demonstrated efficacy in overactive bladder (OAB) symptoms of urge urinary incontinence and urinary frequency. Demonstrated efficacy in reducing micturition frequency. Mean change from baseline in micturition episodes/24 h at week 12. 42;Pooled data from four 12-we...
Market Experience | VESIcare® (solifenacin succinate) Tablets
https://www.vesicarehcp.com/about-VESIcare
VESIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product. Please see additional Important Safety Information below. VESIcare has the most lives with. Preferred brand formulary status. FORMULARY STATUS DOES NOT IMPLY SAFETY OR EFFICACY OF ANY PRODUCT. A product’s placement on a plan’s formulary involves a variety of factors known only to the applicable plan. NEXT: Mechanism of Action. The neu...
Formulary Coverage | VESIcare® (solifenacin succinate) Tablets
https://www.vesicarehcp.com/formulary-coverage
VESIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product. Please see additional Important Safety Information below. Access Program and Services. VESIcare has the most lives with preferred brand formulary status. Preferred and total brand coverage of Commercial plans. FORMULARY STATUS DOES NOT IMPLY SAFETY OR EFFICACY OF ANY PRODUCT. When your patients join the Momentum. Patient is responsibl...
Micturitions | VESIcare® (solifenacin succinate) Tablets
https://www.vesicarehcp.com/micturitions
VESIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product. Please see additional Important Safety Information below. VESIcare has demonstrated efficacy in overactive bladder (OAB) symptoms of urge urinary incontinence and urinary frequency. Demonstrated efficacy in reducing micturition frequency. Mean change from baseline in micturition episodes/24 h at week 12. 42;Pooled data from four 12-we...
3-Day Patient Bladder Diary | VESIcare® (solifenacin succinate) Tablets
https://www.vesicarehcp.com/bladder-diary
VESIcare is contraindicated in patients with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients with hypersensitivity to the product. Please see additional Important Safety Information below. Access Program and Services. VESIcare has the most lives with preferred brand formulary status. Preferred and total brand coverage of Commercial plans. FORMULARY STATUS DOES NOT IMPLY SAFETY OR EFFICACY OF ANY PRODUCT. When your patients join the Momentum. Patient is responsibl...
TOTAL LINKS TO THIS WEBSITE
35
Log In
Please enter your username and password. Register. If you don't have an account. Keep me logged in. I certify that I have taken the required Training. Necessary to request displays. Effective July 1st, all requests for Exhibits and Displays must be submitted through echo. You can access echo through your Fusion. Questions regarding existing or pending portable requests that were submitted through the old system, astellasportables.com. Thank you for your cooperation.
astellasportables.info
astellasportables.net
astellasportables.org
astellasportables.us
Astellas Resource Portal | Patient Care Support
As a part of our commitment to providing support to healthcare professionals. And patients, we’ve developed resources for every stage of patient care. These resources may be:. Customized with your facility information and logo, saved/downloaded, and printed. Used as valuable patient education materials. Accessed in English or Spanish, where available. Help your urology patients understand their symptoms, treatment options, and more. Register for Quick Access! Get immediate access to all your. At least on...
Astell Associates-Home
Arboricultural, environmental and landscape consultants. Astell Associates is an arboricultural and ecological consultancy specialising in all aspects of environmental assessment, design and planning. Extensive knowledge of the planning process and planning law, together with international and national nature conservation law enables us to produce objective reports.
Home Page
This program is managed by Astellas Pharma US, Inc. If you have any questions, concerns, or comments,. Please contact the Astellas Speaker Management Team at 866-270-5886, or e-mail AstellasSpeakers@discoveryworldwide.com. And the flying star logo are trademarks of Astellas Pharma Inc. Enter your e-mail address:. Password instructions will be sent out via e-mail. Your temporary password has been e-mailed to you. Please note this e-mail message may arrive in your spam/junk folder. And choose option 1.
Astellassymposia.com
Astellassymposia.org
Astellas Transplant Europe (ATEU) website | Login
You are now entering the Astellas Transplant Europe website. This website has been initiated, developed and its contents managed by Astellas Pharma Europe Ltd in accordance with the UK ABPI code of practice. By continuing you acknowledge and agree to the Terms of use and Privacy policy. Please confirm that you are a healthcare professional by clicking on the link below:. Yes, I am a healthcare professional. If you are NOT a healthcare professional please click on the link below:.
